Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-
Clinical Trials
Related News

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

First Posted Date
2020-05-08
Last Posted Date
2024-11-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
15
Registration Number
NCT04380545
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

First Posted Date
2020-05-05
Last Posted Date
2023-12-26
Lead Sponsor
Universitätsmedizin Mannheim
Target Recruit Count
342
Registration Number
NCT04375605
Locations
🇩🇪

Unversity Hospital Mannheim, Mannheim, Germany

NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

First Posted Date
2020-05-01
Last Posted Date
2024-04-19
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
200
Registration Number
NCT04371224
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

First Posted Date
2020-04-27
Last Posted Date
2024-01-22
Lead Sponsor
Leap Therapeutics, Inc.
Target Recruit Count
232
Registration Number
NCT04363801
Locations
🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States

and more 45 locations

Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer

First Posted Date
2020-04-24
Last Posted Date
2021-07-19
Lead Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Target Recruit Count
388
Registration Number
NCT04358354
Locations
🇨🇳

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

First Posted Date
2020-04-24
Last Posted Date
2023-08-28
Lead Sponsor
University of Chicago
Target Recruit Count
54
Registration Number
NCT04361708
Locations
🇺🇸

The University of Chicago, Chicago, Illinois, United States

Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma

Phase 2
Active, not recruiting
Conditions
Cancer of Head and Neck
Interventions
Drug: Docetaxel
Drug: Cisplatin
Drug: Fluoro Uracil
First Posted Date
2020-04-22
Last Posted Date
2024-07-10
Lead Sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Target Recruit Count
105
Registration Number
NCT04356170
Locations
🇫🇷

Centre Leon Berard, Lyon, France

Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer

First Posted Date
2020-04-21
Last Posted Date
2021-02-18
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
35
Registration Number
NCT04354662
Locations
🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

First Posted Date
2020-04-09
Last Posted Date
2024-10-26
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
352
Registration Number
NCT04340141
Locations
🇺🇸

Tampa General Hospital, Tampa, Florida, United States

🇺🇸

Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

🇺🇸

Henry Ford Health Providence Novi Hospital, Novi, Michigan, United States

and more 442 locations

A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer

First Posted Date
2020-04-08
Last Posted Date
2020-07-21
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
56
Registration Number
NCT04337879
Locations
🇨🇳

The First Hospital of China Medical University, Shengyang, Liaoning, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy